ACAD — ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 653
- Website: https://www.acadia-pharm.com
Latest SEC filings for ACAD
- 8-K — 2026-10-23
- SCHEDULE 13G — 2026-08-07
- 10-Q — 2026-08-05
- 8-K — 2026-05-29
- 10-Q — 2026-05-07
- 8-K — 2026-05-06
- SCHEDULE 13G/A — 2026-03-26
- 8-K — 2026-03-05
- 8-K — 2026-02-25
- 8-K — 2026-01-13
Latest ACAD news
- — Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight (GlobeNewswire Inc.)
- — Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3? (Zacks Investment Research)
- — INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD (globenewswire.com)
- — Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects? (Zacks Investment Research)
- — Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects? (zacks.com)
- — Reviewing ACADIA Pharmaceuticals (NASDAQ:ACAD) and C4 Therapeutics (NASDAQ:CCCC) (defenseworld.net)
- — 4 CNS Drug Stocks Worth Watching This World Mental Health Day (Zacks Investment Research)
- — INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD (prnewswire.com)
- — INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD (globenewswire.com)
- — Acadia, Zydus patent litigation case looks resolved, says RBC (seekingalpha_market)
Educational tool only — not investment advice.